ConductScience.org, home

Comparison · NCT02159976-ca5c026e

Sequential Therapy vs Modified Bismuth Quadruple Therapy: Counts of Participants Whose Drug Compliance is More Than 85%

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Sequential Therapy vs Modified Bismuth Quadruple Therapy: Counts of Participants Whose Drug Compliance is More Than 85%. Trial comparisons, record NCT02159976-ca5c026e. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02159976-ca5c026e

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.9380.8920.965wilson
Risk in group 20.960.9210.981wilson
Risk difference, group 1 minus group 2-0.023-0.07320.0253newcombe hybrid score
Risk ratio, group 1 over group 20.9760.931.02log
Odds ratio, group 1 over group 20.6180.2341.63log
Number needed to treat, for one fewer participant with the outcome on Sequential Therapy than on Modified Bismuth Quadruple Therapy43.6from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Sequential Therapy
pantoprazole 40mg bid 10 days (D1-D10), amoxicillin 1000mg bid 5 days (D1-D5), clarithromycin 500mg bid 5 days (D6-D10), metronidazole 500mg tid 5 days (D6-D10)~Pantoprazole~Amoxicillin~Clarithromycin~Metronidazole
165176OG000
Group 2Modified Bismuth Quadruple Therapy
pantoprazole 40mg bid 14 days (D1-D14) , amoxicillin 1000mg bid 14 days (D1-D14), tetracycline 1000mg bid 14 days (D1-D14), bismuth 600mg bid 14 days (D1-D14)~Pantoprazole~Amoxicillin~Tetracycline~Bismuth
170177OG001

Outcome

Type
SECONDARY
Title
Counts of Participants Whose Drug Compliance is More Than 85%
Description
Time frame
4 weeks after termination of eradication therapy, up to 6 weeks
Population

Source ClinicalTrials.gov

Trial

Title
Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea
NCT number
NCT02159976
Phases
NA
Conditions
Helicobacter Pylori Infection
Interventions
Pantoprazole, Amoxicillin, Clarithromycin, Metronidazole, Tetracycline, Bismuth
Lead sponsor
Seoul National University Bundang Hospital
Results first posted
2019-05-13

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02159976-ca5c026e